

The final version of this paper was published in *J Clin Endocrinol Metab*, 2012; 97(9):3115-3122

**Association and predictive accuracy of high TSH serum levels in first trimester and adverse pregnancy outcomes**

Francisco J Schneuer<sup>\*1</sup>, Natasha Nassar<sup>1</sup>, Vitomir Tasevski<sup>1,2</sup>, Jonathan M Morris<sup>1</sup> and Christine L Roberts<sup>1</sup>

Email: Francisco J Schneuer<sup>\*1</sup> [francisco.schneuer@sydney.edu.au](mailto:francisco.schneuer@sydney.edu.au)

Address: Building 52, Royal North Shore Hospital, St Leonards NSW 2065, Australia

Telephone: +61 2 9926 6031 Fax: +61 2 9906 6742

\*Corresponding author

<sup>1</sup>Clinical and Population Perinatal Health Research, Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, Australia and <sup>2</sup>Fetal Maternal Medicine (PaLMs), Royal North Shore Hospital, St Leonards, NSW, Australia

**Abbreviated title:** Association of high TSH and adverse pregnancy outcomes

**Key Terms:** Thyrotropin, thyroid disease, pregnancy, pregnancy complications, prenatal diagnosis, cohort studies, infant, newborn, sensitivity and specificity

**Word count:** 3,112

**Funding:** This work was supported by a National Health and Medical Research Council (NHMRC) Project Grant (#632653). CLR is supported by a NHMRC Senior Research Fellowship (#457078) and NN by a NHMRC Career Development Fellowship (#632955)

**Disclosure Summary:** There is no conflict of interest to declare

## **Abstract**

**Context:** High serum levels of thyroid stimulating hormone (TSH) have been associated with adverse pregnancy outcomes by some studies; and not by others.

**Objective:** To assess the association between high levels of TSH in first trimester of pregnancy and adverse pregnancy outcomes; and examine the predictive accuracy as a screening test.

**Setting and Participants:** Serum levels of TSH were measured in a cohort of 2,801 women with a singleton pregnancy attending first trimester Down syndrome screening. Information on maternal and infant outcomes was obtained through record linkage to population-based birth and hospital data. Association between high TSH (>95<sup>th</sup> and >97.5<sup>th</sup> centile) multiple of the median (MoM) levels and risk of adverse pregnancy outcomes was evaluated using multivariable logistic regression and the predictive accuracy of models was assessed.

**Main Outcomes:** Small for gestational age (SGA), preterm birth, preeclampsia, miscarriage and stillbirth.

**Results:** High TSH MoM levels were associated with SGA (<10<sup>th</sup> centile) (adjusted odds ratio (aOR) 1.71; 95% CI 0.99-2.94), preterm birth <37 weeks gestation (aOR 2.59; 95% CI 1.21-5.53), miscarriage (aOR 3.66; 95% CI 1.59-8.44) and a composite measure of any study outcome (aOR 2.10; 95% CI 1.23–3.59). The area under the receiver operator characteristic curves were 0.69 (95% CI 0.65-0.73) for SGA; 0.56 (95% CI 0.51-0.61) for preterm birth, 0.70 (95% CI 0.61-0.79) for miscarriage and 0.63 (95% CI 0.60–0.65) for any adverse pregnancy outcome.

**Conclusions:** High TSH serum levels during first trimester of pregnancy were associated with adverse pregnancy outcomes; however the predictive accuracy was poor. Screening for high TSH levels in first trimester would be of no benefit to identify women at-risk.

## Introduction

The effect of thyroid malfunction in pregnancy and on subsequent pregnancies and infant outcomes is a subject of interest and controversy (1). *In vitro* studies suggest that thyroid hormones contribute directly to early placental development stimulating angiogenesis, and promoting invasion and differentiation of embryonic cells (2, 3). Thyroid hormone (T3) receptors are present in the trophoblast and thyroid hormone transporters are significantly reduced in pregnancies with intrauterine growth restriction (4). These findings attest to a possible effect of abnormal levels of thyroid hormones on the pathological pathways to adverse pregnancy outcomes.

Fetal thyroxine production does not occur until 8-10 weeks, therefore, the fetus depends upon maternal thyroid hormone transfer in early pregnancy for normal brain development (5, 6). Neurological impairment in children has been associated with maternal overt hypothyroidism (7) and hypothyroxinemia (8). Subclinical hypothyroidism is diagnosed in women with thyroid stimulating hormone (TSH) above a statistically defined upper limit of a reference range but normal levels of free thyroxine (fT<sub>4</sub>) (9). Although, some studies have reported increased rates of pregnancy loss (10, 11), placental abruption (12), preterm delivery (12) and preeclampsia (13) in woman with elevated TSH level, other studies have not identified a significant association with any adverse pregnancy outcome (14, 15).

These inconsistent findings have led to conflicting support for screening asymptomatic women for high TSH levels in early pregnancy. Furthermore, studies suggests screening and treating women with subclinical hypothyroidism would be cost-effective if this resulted in improved child neurodevelopment (16, 17). First trimester screening would also provide an ideal opportunity to identify pregnancies at-risk and may be incorporated into existing routine antenatal testing when preventive interventions may be a realistic option. Despite these potential benefits and that a recent study found that screening and treating pregnant women with subclinical hypothyroidism was beneficial (18), current clinical guidelines by the American Thyroid Association highlight that there is

insufficient evidence to recommend it (19). There is also little information on the predictive accuracy of screening for TSH to identify pregnancies at risk.

The aim of this study was to evaluate the association between high maternal TSH levels measured at 10 to 14 weeks of pregnancy and the risk of adverse pregnancy outcomes; and to assess the predictive accuracy of TSH in predicting adverse outcomes in an unselected pregnant population.

## **Methods**

### **Study Population and data sources**

The study population included pregnant women who had first trimester Down syndrome screening between July & October 2006 by The Pacific Laboratory Medicine Services (PaLMs), a pathology screening service in New South Wales (NSW), Australia. This was the state's only public screening service and received samples from throughout NSW. A total of 3,103 serum samples were collected for women undergoing screening at 10-14 weeks gestation in pregnancy and all samples were archived at -80°C.

Serum TSH levels were measured by automated immunoassay system (Siemens IMMULITE® 2000, Siemens Medical Solutions Diagnostics, Los Angeles, CA). The inter and intra assay coefficient of variation was <8% and the reported analytic sensitivity of the immunoassay was 0.004 IU/L. The samples were analysed blind to the clinical outcomes.

Pregnancy and birth information for mothers and babies was ascertained from birth and hospital data and individual data were record-linked to each woman's corresponding laboratory (Down syndrome and TSH) results. Birth information was obtained from the NSW Perinatal Data Collection (PDC), a statutory collection of all livebirths and stillbirths in NSW of at least 400 grams birth weight, or at least 20 weeks gestation. It contains demographic, medical and obstetric information on the mother and information on the labor, delivery and condition of the infant. Hospital data were obtained from the

NSW Admitted Patient Data Collection (APDC), a census of hospital discharges from all NSW public and private hospitals and day procedure centres. It includes demographic, administrative and clinical information for each hospital admission. Information includes reason for admission, significant comorbidities and complications, and procedures performed during the admission. Up to 20 diagnosis and procedure fields were available for each admission and coded according to the 10<sup>th</sup> revision of the International Classification of Diseases – Australian Modification (ICD10-AM) and the 5<sup>th</sup> edition of the Australian Classification of Health Interventions (AHCI) respectively.

In Australia unique identifiers are not available for record linkage of unit record data from multiple datasets (20). Consequently probabilistic linkage methods were utilised. This involves a complex process of blocking and matching combinations of selected variables (such as name, date of birth, address and hospital) using record-linkage software (21). Probability weights are calculated, adjusted for incomplete and missing data, and used to determine correct matches. The validity of the probabilistic record linkage is extremely high with less than 1% of records having an incorrect match (20-23). The NSW Centre for Health Record Linkage conducted the record linkage and identifying information was removed prior to the release of data for analysis. The study was approved by the NSW Population and Health Services Research Ethics Committee.

Linked health information relevant to the pregnancy was available for 2,907 (93.7%) samples.

Importantly, there was no significant difference in TSH levels, maternal age and weight for women whose health information was not available compared to those included in the study. We then excluded 106 women whose blood sample was taken before 10 or after 14 weeks gestation, had a medical abortion, had a twin pregnancy or had an infant with major congenital anomalies. The study outcomes assessed included: small for gestational age (SGA), preterm birth, preeclampsia, miscarriage, stillbirth and a composite outcome of any adverse pregnancy outcome. SGA was defined as birthweight less than the 10<sup>th</sup> centile and less than the 3<sup>rd</sup> centile (severe SGA) of the distribution for gestational age and infant sex (24). Gestational age is reported in the birth data in completed weeks of gestation and determined by the best clinical estimate including early ultrasound (>97%) and

last menstrual period. Preterm birth was defined as delivery at less than 37 weeks and very preterm birth less than 34 weeks gestation. Information on preeclampsia was obtained from the hospital data, based on a diagnosis by the attending clinician that was coded according to ICD10-AM. During the study period, preeclampsia was defined as the onset of hypertension (systolic blood pressure  $\geq 140$  mm Hg and/or diastolic blood pressure  $\geq 90$  mm Hg) from 20 weeks' gestation onwards accompanied by proteinuria (25). Miscarriage was defined as a spontaneous pregnancy loss between 10-20 weeks gestation and were identified from hospital data. Stillbirth was defined as a pregnancy loss after 20 weeks gestation and were identified from birth data. A composite 'any adverse pregnancy outcome' variable was also developed comprising the occurrence of any of the pregnancy outcomes from above.

Explanatory variables applied in this study included; maternal age, parity (nulliparous/multiparous), smoking during pregnancy (yes/no), maternal weight (kilograms) and free  $\beta$ -hCG (corrected for gestational age at testing and maternal weight) collected at Down syndrome screening. Only factors that are well and accurately reported were included in the analyses (20, 26, 27). Maternal weight was missing in 550 (20%) of the records. We conducted a sensitivity analysis comparing model results when we included women with records missing weight assigning them with the mean weight of the total population, against excluding them from the analysis. As no significant difference was found, mean weight was applied to those missing values and included in the analyses. Other missing data were infrequent: there were no records with missing maternal age or parity. Smoking was missing in 58 records (2.1%) and there were 4 missing records for free  $\beta$ -hCG (0.1%) which were excluded from the analysis. Only SGA analyses were affected by the missing data exclusions and importantly, there were no SGA cases with missing data.

### **Statistical analysis**

We compared women with each study outcome to those without the adverse outcome. Descriptive statistics were calculated and differences between groups were tested using Chi-squared and Fisher's exact test for categorical variables and student's t-test for continuous variables. Given a non linear distribution of the serum levels of TSH, a non-parametric Kruskal-Wallis test was used to determine

differences among medians of gestational age at testing grouped in weeks, and the Wilcoxon rank-sum test to determine differences in median TSH serum levels between mothers with and without each outcome of interest.

As TSH differed by gestational week at testing, we standardized TSH levels using Multiple of the Medians (MoM) as described by Cuckle and Wald(28). A regression model was fitted to the medians for each week of gestation at testing for the unaffected group and each individual value was divided by its regressed value to calculate each MoM. Logistic regression was used to determine the association between maternal TSH (MoM) and adverse pregnancy outcomes. TSH (MoM) levels were dichotomized to identify mothers with high values of TSH using percentile cut-offs above the 95<sup>th</sup> (2.92, n=140) and 97.5<sup>th</sup> (3.74, n=70) percentiles. Backward elimination method was then used to fit models with only significant explanatory variables retained. Results are reported as adjusted odds ratios (aOR) with 95 percent confidence intervals (95% CI).

The diagnostic performance of significant outcomes was assessed by examining the area under the Receiver Operating Characteristics (ROC) curves (AUC), derived from logistic regression analysis and using the TSH (MoM) 97.5<sup>th</sup> centile cut-off, as this was considered to be more clinically meaningful. AUC was calculated for both univariate and multivariable models and results examined whether the test performed better than chance (0.5). A standardized scale was used to assess the AUC result (29) where an AUC of 1 represents a perfect test, 0.9 – <1 an excellent test, 0.8 – <0.9 a good test, 0.7 – <0.8 a fair test, 0.6 – <0.7 a poor test and 0.5 – <0.6 a worthless test. Finally, estimates of predictive accuracy were calculated including sensitivity, specificity, positive (PPV) and negative predictive values ( NPV) with exact binominal confidence intervals (30), based on the population prevalence of each outcome. Statistical analysis was performed using SAS software 9.2 (SAS Institute Inc., Cary, NC, USA) and a p-value of <0.05 was considered statistically significant.

## Results

In total 2,801 women were included in the analysis. Table 1 presents the maternal characteristics by pregnancy outcome. The mean maternal age was 32.8 (SD 4.7) years, 1266 (45.2%) women were nulliparous and 168 (6.1%) smoked during pregnancy. There were 218 (7.8%) SGA infants, 142 (5.1%) preterm births, 73 (2.6%) women diagnosed with preeclampsia, 42 (1.5%) women had a miscarriage and 12 (0.4%) stillbirths. The median TSH levels for the total population was 0.84 UI/L (5–95<sup>th</sup> centile range: 0.08 – 2.37 UI/L) and for TSH (MoM) was 1.02 (5–95<sup>th</sup> centile range: 0.11 – 2.92). Compared with unaffected pregnancies, median TSH levels were significantly higher in women with SGA <10<sup>th</sup> centile infants ( $P<0.01$ ) and in women who had a preterm birth (<37 weeks) ( $P<0.05$ ).

The results of logistic regression analysis of TSH MoM for all pregnancy outcomes are shown in Table 2. High TSH MoM levels (>95<sup>th</sup> centile) were associated with increased risk of SGA (aOR 1.71; 95% CI 0.99 – 2.94), preterm birth <37 weeks (aOR 1.86; 95% CI 1.00 – 3.45) and miscarriage (aOR 3.66; 95% CI 1.59 – 8.44); and there was a significant increased risk of preterm birth <37 weeks for women with levels above the 97.5<sup>th</sup> percentile (aOR 2.59; 95% CI 1.21 – 5.53). Overall high TSH MoM levels >95<sup>th</sup> and >97.5<sup>th</sup> centile were associated with a 1.6 and 2.1 fold risk of any adverse pregnancy outcome, respectively (Table 2). There was no significant association between high TSH levels and SGA <3<sup>rd</sup> centile, very preterm birth (<34 weeks), preeclampsia and stillbirth.

Figure 1 presents the ROC curves for the adjusted models based on TSH MoM levels >97.5<sup>th</sup> centile and Table 3 presents the predictive accuracy results for SGA <10<sup>th</sup> centile, preterm birth (<37 weeks), miscarriage and any adverse pregnancy outcome. Assessment of the accuracy of high TSH levels (>97.5<sup>th</sup> centile) revealed it performed poorly in predicting adverse pregnancy outcomes. The area under the curve (AUC) of most univariate models were not different from chance; and after adjusting for risk factors, the predictive accuracy remained inadequate in identifying subsequent pregnancy complications.



## Discussion

Our study highlights that women with high TSH levels at 10 to 14 weeks of pregnancy are at increased risk of experiencing an adverse pregnancy outcome, specially, having a small for gestational age infant (SGA <10<sup>th</sup> centile), preterm birth (<37 weeks) or miscarriage. Although we found no significant association for more severe outcomes of SGA <3<sup>rd</sup> centile, very preterm birth (<34 weeks), preeclampsia or stillbirth. Moreover, our results indicate that the predictive accuracy of high TSH levels was poor. Inclusion of additional maternal information and serum biomarker,  $\beta$ -hCG, did not improve results.

Overall, our findings do not support routine screening for high TSH levels to identify adverse pregnancy outcomes. Application of our results to a general maternity population of 10,000 women with an estimated 10% prevalence of SGA reveal that screening for high levels of TSH in first trimester would identify 2,130 women at risk but only 420 would truly have a SGA infant. 1,710 would be falsely labelled and a further 580 would be missed altogether. This is supported by a recent trial comparing universal screening for TSH with a high risk case-finding approach for the detection and treatment of thyroid hormone dysfunction in pregnancy. The trial found no significant difference in adverse pregnancy outcomes between groups, although women from the universal screening group that were low-risk, hypothyroid and treated had less adverse pregnancy outcomes compared with women from the case-finding group that were low-risk, hypothyroid (non-identified) and non-treated (18). These findings, as well as our own results, suggest that the majority of women having adverse pregnancy outcomes do not have elevated TSH and are euthyroid. Thus, TSH screening is likely to fail to identify the majority of women at risk because high TSH levels may represent only one specific pathological pathway, and the causes of adverse pregnancy outcomes are heterogeneous and multifactorial (31).

To date, there have been a number of studies investigating the association between high TSH levels and adverse pregnancy outcomes and findings have been inconsistent. Although, our results suggest some evidence of an increased risk of SGA <10<sup>th</sup> centile and preterm birth (<37 weeks), these may have been chance findings as we did not find any relationship for more severe cases, SGA <3<sup>rd</sup> centile

and very preterm birth <34 weeks; however these numbers were small. The strong association between high TSH levels and miscarriage has not been reported by previous studies, but should be replicated in future studies. Although, a study of euthyroid pregnant women with autoimmune thyroid disease found a reduction in miscarriage rates in a group of women treated with Levothyroxine compared with a non-treated group that had higher TSH levels, suggesting that high TSH levels may be a determinant risk factor (32). Also, two studies have found increased risk of fetal loss, which included miscarriages and/or stillbirths (10, 11). Overall, our findings suggest there is significant association between high TSH levels and some adverse pregnancy outcomes examined. Variation in study findings may be explained by differences in study design, population sample size or representativeness of the clinical population, ranging from case-control studies of 167 women to large cohort studies testing over 17,000 women; and differences in demographic characteristics such as maternal age, racial origin or parity.

Serum TSH was also variable across studies. We identified a 95<sup>th</sup> percentile cut point of 2.37 IU/L, although there is a degree of mild iodine deficiency in NSW (33) results are consistent with an iodine-replete population and reference intervals reported for first trimester of pregnancy in Western Australia (34). However, other studies have used various (95<sup>th</sup> and 97.5<sup>th</sup> centile) cut points to define high TSH levels, ranging from 2.78 to 4.8 IU/L (12, 14, 34-36). These differences suggest significant variability in distribution of TSH serum levels that may be explained by different levels of iodine status in populations, different immunoassay used in the analysis and underlying ethnic differences (37).

Strengths of this study were the assessment of a large sample and unselected consecutive cohort of women attending first trimester screening. Record linkage of laboratory to birth and hospital data ensured follow up and ascertainment of pregnancy outcomes with only minimal missing information. Missing health and pregnancy information was mostly attributable to women residing in bordering towns and giving birth in hospitals out of state. Nevertheless, women with missing health information had similar characteristics compared to those included in the study. Another strength was that the

exposure was measured independently of the outcome and were adjusted for  $\beta$ -hCG, with testing performed blinded to outcome. Low  $\beta$ -hCG has been identified as a risk factor or marker for miscarriage, preterm delivery and fetal growth restriction (26, 38); and maternal TSH function in pregnancy can be influenced by the thyrotrophic activity of  $\beta$ -hCG. Both hormones have similar structure, sharing a common  $\alpha$ -subunit, and a reduction in TSH secretion in response to rising  $\beta$ -hCG levels in the first trimester of pregnancy has been previously reported (1, 39). However, one of the limitations of our study was the lack of clinical information such as supplementation use in pregnancy. Nevertheless, women in our study appeared to be healthier, reflected by the lower prevalence of adverse pregnancy outcomes compared with the maternity population in NSW (5.1% vs. 5.9% preterm birth, 7.8% versus 10% SGA infants, 2.6% versus 3.1% preeclampsia) (40). Finally, miscarriages were underrepresented because these were limited to only those occurring post-10 weeks gestation and not all those women are admitted to hospital for such an event.

In our study women were not tested for free thyroxine ( $fT_4$ ), therefore, it was only possible to categorize woman as having high TSH levels but not to separate women with subclinical (high TSH and  $fT_4$  within normal range) and clinical hypothyroidism (high TSH with  $fT_4 < 5^{\text{th}}$  centile). Women with TSH levels of  $>10$  mIU/L, irrespective of their  $fT_4$  levels, are considered to have clinical hypothyroidism (19) In our population only four woman had TSH levels of  $>10$  mIU/L, consequently, the group was considered not significant to conduct a sub analysis. Thyroid antibody presence (TPO-Ab or TG-Ab) was also not tested in our study. A recent meta-analysis of studies (41), found that miscarriage and preterm birth was associated with the presence of thyroid antibodies and that antibody positive women have, on average, higher TSH levels compared to antibody negative women. However, the predictive usefulness of high TSH levels for miscarriage is questionable due to the very limited time to intervention.

Overall, our findings suggest that elevated TSH levels are associated with an increased risk of adverse pregnancy outcomes. Despite the positive associations, the poor predictive accuracy of our models

suggests that wide-spread screening for high levels of TSH in first trimester of pregnancy would not efficiently identify women at-risk of adverse pregnancy outcomes.

### **Acknowledgements**

We thank the NSW Department of Health and the NSW Centre for Health Record Linkage for record linkage, and for access to the population health data. Cyrille Guilbert for preparation of samples and Samantha Lain for preparation of data for linkage.

### **References**

1. **Kennedy RL, Malabu UH, Jarrod G, Nigam P, Kannan K, Rane A** 2010 Thyroid function and pregnancy: before, during and beyond. *J Obstet Gynaecol* 30:774-783
2. **Burrow GN, Fisher DA, Larsen PR** 1994 Maternal and fetal thyroid function. *N Engl J Med* 331:1072-1078
3. **Maruo T, Matsuo H, Mochizuki M** 1991 Thyroid hormone as a biological amplifier of differentiated trophoblast function in early pregnancy. *Acta Endocrinol (Copenh)* 125:58-66
4. **Loubiere LS, Vasilopoulou E, Bulmer JN, Taylor PM, Stieger B, Verrey F, McCabe CJ, Franklyn JA, Kilby MD, Chan SY** 2010 Expression of thyroid hormone transporters in the human placenta and changes associated with intrauterine growth restriction. *Placenta* 31:295-304
5. **Lazarus JH** 1999 Thyroid hormones and neurodevelopment. *Clin Endocrinol (Oxf)* 50:147-148
6. **Morreale de Escobar G, Obregon MJ, Escobar del Rey F** 2004 Role of thyroid hormone during early brain development. *Eur J Endocrinol* 151 Suppl 3:U25-37
7. **Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ** 1999 Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med* 341:549-555

8. **Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL, de Vijlder JJ** 2003 Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study. *Clin Endocrinol (Oxf)* 59:282-288
9. **Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ** 2004 Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *Jama* 291:228-238
10. **Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, Bonsel GJ, Vrijkotte TGM** 2009 Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. *Eur J Endocrinol* 160:985-991
11. **Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A** 2010 Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. *J Clin Endocrinol Metab* 95:E44-48
12. **Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ, Cunningham FG** 2005 Subclinical hypothyroidism and pregnancy outcomes. *Obstet Gynecol* 105:239-245
13. **Ashoor G, Maiz N, Rotas M, Kametas NA, Nicolaides KH** 2010 Maternal thyroid function at 11 to 13 weeks of gestation and subsequent development of preeclampsia. *Prenat Diagn* 30:1032-1038
14. **Cleary-Goldman J, Malone FD, Lambert-Messerlian G, Sullivan L, Canick J, Porter TF, Luthy D, Gross S, Bianchi DW, D'Alton ME** 2008 Maternal thyroid hypofunction and pregnancy outcome. *Obstet Gynecol* 112:85-92
15. **Mannisto T, Vaarasmaki M, Pouta A, Hartikainen AL, Ruokonen A, Surcel HM, Bloigu A, Jarvelin MR, Suvanto E** 2010 Thyroid dysfunction and autoantibodies during pregnancy as predictive factors of pregnancy complications and maternal morbidity in later life. *J Clin Endocrinol Metab* 95:1084-1094
16. **Dosiou C, Barnes J, Schwartz A, Negro R, Crapo L, Stagnaro-Green A** 2012 Cost-Effectiveness of Universal and Risk-Based Screening for Autoimmune Thyroid Disease in Pregnant Women. *J Clin Endocrinol Metab* 97

17. **Thung SF, Funai EF, Grobman WA** 2009 The cost-effectiveness of universal screening in pregnancy for subclinical hypothyroidism. *Am J Obstet Gynecol* 200:267 e261-267
18. **Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A** 2010 Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. *The Journal of clinical endocrinology and metabolism* 95:1699-1707
19. **Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W** 2011 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. *Thyroid* 21:1081-1125
20. **Centre for Health Record Linkage** 2009 Quality assurance in record linkage. In. <http://www.cherel.org.au/CHeReLQualityAssuranceJuly2008.pdf>
21. **Meray N, Reitsma JB, Ravelli AC, Bonsel GJ** 2007 Probabilistic record linkage is a valid and transparent tool to combine databases without a patient identification number. *J Clin Epidemiol* 60:883-891
22. **Declercq E, Barger M, Cabral HJ, Evans SR, Kotelchuck M, Simon C, Weiss J, Heffner LJ** 2007 Maternal outcomes associated with planned primary cesarean births compared with planned vaginal births. *Obstet Gynecol* 109:669-677
23. **Ford JB, Roberts CL, Algert CS, Bowen JR, Bajuk B, Henderson-Smart DJ** 2007 Using hospital discharge data for determining neonatal morbidity and mortality: a validation study. *BMC Health Serv Res* 7:188
24. **Roberts CL, Lancaster PA** 1999 Australian national birthweight percentiles by gestational age. *Med J Aust* 170:114-118
25. **Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM** 2001 The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). *Hypertension in pregnancy : official journal of the International Society for the Study of Hypertension in Pregnancy* 20:IX-XIV

26. **Lain SJ, Algert CS, Tasevski V, Morris JM, Roberts CL** 2009 Record linkage to obtain birth outcomes for the evaluation of screening biomarkers in pregnancy: a feasibility study. *BMC Med Res Methodol* 9:48
27. **Roberts CL, Bell JC, Ford JB, Hadfield RM, Algert CS, Morris JM** 2008 The accuracy of reporting of the hypertensive disorders of pregnancy in population health data. *Hypertens Pregnancy* 27:285-297
28. **Cuckle, Wald NJ** 2000 Principles of Screening: In: Wald N, Leck I, editors. *Antenatal & Neonatal Screening*. 2nd ed. Oxford: Oxford University Press; pp. 3-22
29. **Swets JA** 1988 Measuring the accuracy of diagnostic systems. *Science* 240:1285-1293
30. **Cha S** 2005 Calculate sensitivity and specificity: Mayo Clinic College of Medicine. In. <http://cancercenter.mayo.edu/mayo/research/biostat/upload/senspe.sas> (SAS Macro)
31. **Simmons LE, Rubens CE, Darmstadt GL, Gravett MG** 2010 Preventing preterm birth and neonatal mortality: exploring the epidemiology, causes, and interventions. *Semin Perinatol* 34:408-415
32. **Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H** 2006 Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. *The Journal of clinical endocrinology and metabolism* 91:2587-2591
33. **Wilcken BM, Wiley VC** 2011 Increased iodine deficiency in Victoria, Australia: analysis of neonatal thyroid-stimulating hormone data, 2001 to 2006. *Med J Aust* 194:209-210
34. **Gilbert RM, Hadlow NC, Walsh JP, Fletcher SJ, Brown SJ, Stuckey BG, Lim EM** 2008 Assessment of thyroid function during pregnancy: first-trimester (weeks 9-13) reference intervals derived from Western Australian women. *Med J Aust* 189:250-253
35. **Mannisto T, Vaarasmaki M, Pouta A, Hartikainen AL, Ruokonen A, Surcel HM, Bloigu A, Jarvelin MR, Suvanto-Luukkonen E** 2009 Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: a prospective population-based cohort study. *J Clin Endocrinol Metab* 94:772-779

36. **Springer D, Zima T, Limanova Z** 2009 Reference intervals in evaluation of maternal thyroid function during the first trimester of pregnancy. *Eur J Endocrinol* 160:791-797
37. **Walker JA, Illions EH, Huddleston JF, Smallridge RC** 2005 Racial comparisons of thyroid function and autoimmunity during pregnancy and the postpartum period. *Obstet Gynecol* 106:1365-1371
38. **van Ravenswaaij R, Tesselaar-van der Goot M, de Wolf S, van Leeuwen-Spruijt M, Visser GH, Schielen PC** 2011 First-trimester serum PAPP-A and fbeta-hCG concentrations and other maternal characteristics to establish logistic regression-based predictive rules for adverse pregnancy outcome. *Prenat Diagn* 31:50-57
39. **Haddow JE, McClain MR, Lambert-Messerlian G, Palomaki GE, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, D'Alton ME** 2008 Variability in thyroid-stimulating hormone suppression by human chorionic [corrected] gonadotropin during early pregnancy. *The Journal of clinical endocrinology and metabolism* 93:3341-3347
40. **Centre for Epidemiology and Research NSWDoH** 2010 New South Wales Mothers and Babies 2007. *NSW Public Health Bull* 21(S1)
41. **Prummel MF, Wiersinga WM** 2004 Thyroid autoimmunity and miscarriage. *Eur J Endocrinol* 150:751-755



**Table 1:** Maternal characteristics by pregnancy outcome

<b>Maternal Characteristics (N=2801)</b>	<b>Unaffected pregnancies N=2357 n (%)</b>	<b>SGA &lt;10<sup>th</sup> N=218 n (%)</b>	<b>SGA &lt;3<sup>rd</sup> N=57 n (%)</b>	<b>Preterm birth &lt;37 weeks N= 142 n (%)</b>	<b>Preterm birth &lt;34 weeks N= 36 n (%)</b>	<b>Preeclampsia N= 73 n (%)</b>	<b>Miscarriage N= 42 n (%)</b>	<b>Stillbirth N= 12 n (%)</b>
<b>Age &lt;35 years</b>	1577 (66.9)	139 (63.8)	33 (57.9)	92 (64.8)	25 (69.4)	55 (75.3)	24 (57.1)	8 (66.7)
<b>Age ≥35 years</b>	780 (33.1)	79 (36.2)	24 (42.1)	50 (35.2)	11 (30.56)	18 (24.7)	18 (42.9)	4 (33.3)
<b>Mean weight (SD)</b>	67.4 (14.4)	61.0 (11.8)**	59.4 (11.2)**	67.1 (14.6)	66.4 (11.7)	72.9 (16.7)	67.5 (16.5)	65.4 (4.5)
<b>Nulliparous</b>	1018 (43.2)	129 (59.2)	34 (59.7)	66 (46.5)	13 (36.1)	48 (65.8)	23 (54.8)	6 (50.0)
<b>Smoking</b>	133 (5.7)	25 (11.5)	9 (15.8)	11 (7.9)	2 (5.6)	1 (1.4)	-	1 (11.1)
<b>TSH (UI/L) Median (5<sup>th</sup> - 95<sup>th</sup>)</b>	0.82 (0.08 - 2.22)	0.96 (0.09 - 2.83)**	0.84 (0.10 - 2.78)	0.92 (0.14 - 3.22)*	0.87 (0.14 - 2.96)	0.90 (0.21 - 2.24)	0.95 (0.05 - 3.33)	0.93 (0.23 - 2.01)
<b>TSH MoM Median (5<sup>th</sup> - 95<sup>th</sup>)</b>	1.00 (0.09 - 2.78)	1.15 (0.11 - 3.61)**	1.02 (0.12 - 3.36)	1.11 (0.16 - 4.00)*	1.05 (0.16 - 3.66)	1.15 (0.30 - 2.89)	1.13 (0.06 - 4.12)	1.12 (0.28 - 2.35)
<b>TSH MoM &gt;95<sup>th</sup> centile</b>	106 (4.8)	17 (8.1)	4 (7.1)	12 (8.8)	3 (8.3)	3 (4.2)	7 (18)	0
<b>TSH MoM 5<sup>th</sup> - 95<sup>th</sup> centile</b>	2127 (95.3)	192 (91.9)	52 (92.9)	125 (91.2)	33 (91.7)	68 (95.8)	32 (82.1)	12 (100)

P<0.05, \*\*P<0.01, compared with unaffected women; MoM: Multiple of the median; SGA: Small for gestational age

**Table 2:** Logistic Regression results of  
TSH MoM on adverse pregnancy outcomes

<b>Birth Outcome</b>	<b>High TSH cases</b>	<b>Adj OR (95% CI)*</b>	<b>P value</b>
<b>SGA &lt;10<sup>th</sup> centile</b>			
>95 <sup>th</sup> (MoM=2.92)	17	1.71 (0.99 - 2.94)	0.05
>97.5 <sup>th</sup> (MoM=3.74)	9	1.76 (0.84 - 3.67)	0.13
<b>SGA &lt;3<sup>rd</sup> centile</b>			
>95 <sup>th</sup> (MoM=2.92)	4	1.46 (0.51 - 4.14)	0.48
>97.5 <sup>th</sup> (MoM=3.74)	2	1.33 (0.31 - 5.70)	0.70
<b>Preterm Birth (&lt;37 weeks)</b>			
>95 <sup>th</sup> (MoM=2.92)	12	1.86 (1.00 - 3.45)	0.05
>97.5 <sup>th</sup> (MoM=3.74)	8	2.59 (1.21 - 5.53)	0.01
<b>Preterm Birth (&lt;34 weeks)</b>			
>95 <sup>th</sup> (MoM=2.92)	3	1.77 (0.54 - 5.85)	0.35
>97.5 <sup>th</sup> (MoM=3.74)	1	NA	NA
<b>Preeclampsia</b>			
>95 <sup>th</sup> (MoM=2.92)	3	0.84 (0.26 - 2.72)	0.77
>97.5 <sup>th</sup> (MoM=3.74)	1	NA	NA
<b>Miscarriage</b>			
>95 <sup>th</sup> (MoM=2.92)	7	3.66 (1.59 - 8.44)	0.002
>97.5 <sup>th</sup> (MoM=3.74)	3	3.06 (0.92 - 10.22)	0.07
<b>Stillbirth</b>			
>95 <sup>th</sup> (MoM=2.92)	0	NA	NA
>97.5 <sup>th</sup> (MoM=3.74)	0	NA	NA
<b>Any adverse outcome</b>			
>95 <sup>th</sup> (MoM=2.92)	34	1.64 (1.10 - 2.47)	0.02
>97.5 <sup>th</sup> (MoM=3.74)	20	2.10 (1.23 - 3.59)	0.01

\* Adjusted for maternal age, maternal weight, smoking,  
parity or free  $\beta$ -hCG

SGA: Small for gestational age

**Table 3:** Screening results of TSH (MoM) >97.5<sup>th</sup> centile predicting adverse pregnancy

outcomes

<b>Birth outcome</b>	<b>AUC (95% CI)</b>	<b>P-value</b>	<b>Sensitivity (%) (95%CI)</b>	<b>Specificity (%) (95%CI)</b>	<b>PPV (%) (95%CI)</b>	<b>NPV (%) (95%CI)</b>	<b>LR (+)</b>
<b>SGA &lt;10<sup>th</sup> centile</b>							
<b>Univariate</b>	0.51 (0.50 - 0.52)	0.2	4.1 (1.9 - 7.7)	97.7 (97.0 - 98.2)	13.4 (6.3 - 24.0)	92.2 (91.1 - 93.2)	1.79
<b>Adjusted</b>	0.69 (0.65 - 0.73)	<0.001	71.1 (64.9 - 77.3)	55.7 (53.8 - 57.7)	12.2 (10.5 - 14.2)	95.7 (94.6 - 96.7)	1.61
<b>Preterm Birth (&lt;37 weeks)</b>							
<b>Univariate</b>	0.52 (0.50 - 0.54)	0.08	5.6 (2.5 - 10.8)	97.7 (97.1 - 98.3)	11.9 (5.3 - 22.2)	95.0 (94.1 - 95.8)	2.49
<b>Adjusted</b>	0.56 (0.51 - 0.61)	0.02	69.7 (61.5 - 77.1)	34.4 (32.6 - 36.3)	5.5 (4.5 - 6.6)	95.4 (93.9 - 96.7)	1.06
<b>Miscarriage</b>							
<b>Univariate</b>	0.52 (0.48 - 0.56)	0.24	7.1 (1.5 - 19.5)	97.6 (96.9 - 98.1)	4.3 (0.9 - 12.0)	98.6 (98.1 - 99.0)	2.94
<b>Adjusted</b>	0.70 (0.61 - 0.79)	<0.001	69.0 (52.9 - 82.4)	54.8 (52.9 - 56.7)	2.3 (1.5 - 3.3)	99.1 (98.5 - 99.5)	1.53
<b>Any adverse outcome</b>							
<b>Univariate</b>	0.51 (0.50 - 0.52)	0.02	4.5 (2.8 - 6.9)	97.9 (97.2 - 98.4)	28.6 (18.4 - 40.6)	84.5 (83.1 - 85.8)	2.14
<b>Adjusted</b>	0.63 (0.60 - 0.65)	<0.001	75.8 (71.6 - 79.8)	41.4 (39.4 - 43.4)	19.6 (17.7 - 21.5)	90.1 (88.2 - 91.8)	1.29

AUC: area under the Receiver Operating Characteristics (ROC) curves

AUC are test for significance against chance (0.5)

Models were adjusted for maternal age, weight, smoking, parity or free  $\beta$ -hCG

SGA: Small for gestational age; PPV: Positive predictive value; NPV: Negative predictive value;

LR (+): Positive likelihood ratio.